Platinum Industries Reports 14.8% Revenue Growth Despite Auditor Qualification

Revenue for FY26 reached ₹4,504.41 million, up from ₹3,922.61 million in the previous year. Profit After Tax rose to ₹512.3 million compared to ₹493.93 million in FY25.

Reader Takeaway: Revenue growth remains strong through capacity expansion, but EBITDA margins tightened and an auditor qualification warrants scrutiny.

What just happened

Platinum Industries announced its financial results for FY26 and scheduled its 6th Annual General Meeting for September 24, 2026. The company successfully operationalized its new 60,000 MT capacity at Palghar Unit II. Simultaneously, the management announced a shift into the life sciences sector through the incorporation of a new subsidiary, Rivadu Lifesciences.

Why this matters

The company’s top-line growth indicates successful scaling of its manufacturing capabilities. However, EBITDA margins contracted from 14.6% to 13.3%. Management cited higher employee costs and initial overheads from the new Palghar unit as the primary reasons for this compression.

Risks to watch

The independent auditor has issued a qualification regarding a ₹98.19 million insurance claim linked to a fire at a subsidiary, 'Platinum Polymers and Additives.' The auditors could not verify the carrying value of investments and loans related to this entity. Investors should track the resolution of this claim as it affects the company's financial reporting accuracy.

Future Outlook

The management has set an ambitious revenue growth target of approximately 40% for FY27. Furthermore, the company expects a 35% CAGR between FY26 and FY29. A key component of this growth is the upcoming 60,000 MTPA greenfield project in Egypt, scheduled for commissioning in FY27, which aims to optimize logistics.

Context metrics

• Net Worth: Increased by 14.9% to ₹4,550.94 million.
• Capacity: Palghar Unit II commercial production began in May 2026.
• Subsidiary: Rivadu Lifesciences incorporated March 2026.